Sutro Biopharma (NASDAQ:STRO) Releases Quarterly Earnings Results

Sutro Biopharma (NASDAQ:STRO) released its quarterly earnings data on Thursday. The company reported ($2.96) earnings per share for the quarter, RTT News reports. Sutro Biopharma had a negative net margin of 77.01% and a negative return on equity of 101.89%. During the same period in the prior year, the firm posted ($1.78) EPS.

Sutro Biopharma Stock Down 6.7 %

Shares of Sutro Biopharma stock opened at $1.25 on Friday. Sutro Biopharma has a 12-month low of $1.25 and a 12-month high of $6.13. The stock has a market cap of $103.07 million, a P/E ratio of -0.78 and a beta of 1.22. The business’s 50 day moving average is $1.79 and its 200-day moving average is $2.79.

Wall Street Analyst Weigh In

A number of research firms have weighed in on STRO. Wedbush reaffirmed an “outperform” rating and set a $8.00 price target on shares of Sutro Biopharma in a research report on Tuesday, December 10th. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Sutro Biopharma in a research report on Monday, November 18th. JMP Securities reaffirmed a “market outperform” rating and set a $17.00 price target on shares of Sutro Biopharma in a research report on Wednesday, December 11th. Finally, Wells Fargo & Company reduced their price target on Sutro Biopharma from $5.00 to $4.00 and set an “equal weight” rating for the company in a research report on Wednesday, December 11th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $11.13.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.